Afnan Sultan Alshehri

Aseer Central Hospital, Saudi Arabia

Title: Atypical Dermatitis Herpetiform and Scalp Psoriasis in Ulcerative Colitis Patient Treated With Adalimumab

Abstract

Adalimumab is a blocker of tumor necrosis factor (TNF)-alpha with established efficacy in the treatment of ulcerative colitis. However, literature indicated that adalimumab can, occasionally, induce paradoxical psoriasis reactions and, very rarely, dermatitis herpetiformis. We present a unique case of a 26-year-old female patient who developed a combination of dermatitis herpetiformis and scalp psoriasis paradoxically as a result of adalimumab treatment for ulcerative colitis. To the best of our knowledge, this is the first case of such a combination within the context of adalimumab therapy. The etiopathological underpinning of such a reaction remains elusive but is speculated to be complex and involves the interaction of several immunological and dermatological mechanisms. Adalimumab therapy is associated with a genuine risk for the development of paradoxical psoriasis and dermatitis herpetiformis. We, through this case report, added to the evidence confirming such an association. Clinicians should follow these potential adverse effects and make every effort to warn patients of their likelihood.

Biography

Afnan Alshehri completed her MBBS at the age of 26 years from King Khalid University, Saudi Arabia in 2021. Willing to continue my career as a dermatologist. I am Working Now As a Resident. This topic is an interesting case I saw it at the clinic and we were so excited to share it.

4th International Conference on Global Healthcare and Nutrition

Afnan Sultan Alshehri

Title: Atypical Dermatitis Herpetiform and Scalp Psoriasis in Ulcerative Colitis Patient Treated With Adalimumab

Abstract

Biography

Organization Location

Mail us at

Our Social Presence

Call us at